丹红注射液治疗脑梗死临床疗效和安全性的Meta分析

Meta-analysis on the efficacy and safety of Danhong injection in the treatment of cerebral infarction

采用RevMan5．0软件，对2006年1月至2010年12月间国内正式刊载且质量评级在B级以上的27篇随机对照试验的文献进行Meta分析。结果显示，丹红注射液的临床综合疗效明显优于单方药组（丹参、复方丹参注射液）组（RR=1．21，95％CI=1．17～1．26）；丹红注射液治疗后患者的神经功能缺损评分及血液流变学指标均明显低于对照组（P〈0．01）。17篇文献均描述治疗组无明显不良反应。提示丹红注射液治疗脑梗死的临床疗效和安全性有一定优势。

To evaluate the clinical efficacy and safety of Danhong injection in the treatment of cerebral infarction. A total of 27 randomized controlled trials were retrieved from the literature and analyzed by Meta-analysis with RevMan 5.0 software. All were at level B or above after quality assessment. The clinical efficacy of Danhong injection was better than that of the control group in the treatment of cerebral infarefion（RR = 1.21, 95% CI：1.17 - 1.26）. After the administration of Danhong injection, the score of National Institute of Neurological Disorders and Stroke （NIHSS） and hemorrheologic indices were significantly lower than those of the control group （ P 〈 0. 01 ）. There was no obvious adverse reaction. The clinical efficacy and safety of Danhong injection have marked advantages over Danshen and Fufang Dansheng injection in the treatment of cerebral infarction.